Consistently, a phase II clinical trial with the pan-AKT inhibitor MK2206 on recurrent and metastatic HNSCC resulted in a partial response and was not moved to phase III so far (ClinicalTrials.gov identifier NCT01349933). The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.